Deficit accumulation frailty index (DAFI) and treatment tolerability in AML: Data from CALGB 11001 and 11002 (Alliance)
Blood Adv
.
2024 Nov 27:bloodadvances.2024014367.
doi: 10.1182/bloodadvances.2024014367.
Online ahead of print.
Authors
Catherine Lai
1
,
Minji Lee
2
,
Olivia Bobek
2
,
Jennifer Le-Rademacher
2
,
Sumithra J Mandrekar
2
,
Gail J Roboz
3
,
Geoffrey L Uy
4
,
Jeanne Mandelblatt
5
,
Heidi D Klepin
6
Affiliations
1
University of Pennsylvania, Philidelphia, Pennsylvania, United States.
2
Mayo Clinic, Rochester, Minnesota, United States.
3
Weill Medical College of Cornell University, New York, New York, United States.
4
Division of Oncology, Washington University School of Medicine, Saint Louis, Missouri, United States.
5
Georgetown University, Washington DC, District of Columbia, United States.
6
Wake Forest School of Medicine, Winston Salem, North Carolina, United States.
PMID:
39602659
DOI:
10.1182/bloodadvances.2024014367
No abstract available
Grants and funding
R01 CA127617/CA/NCI NIH HHS/United States
R56 AG068086/AG/NIA NIH HHS/United States
UG1 CA189823/CA/NCI NIH HHS/United States
R01 CA129769/CA/NCI NIH HHS/United States
R35 CA283926/CA/NCI NIH HHS/United States
UG1 CA189824/CA/NCI NIH HHS/United States
R01 AG068193/AG/NIA NIH HHS/United States
R35 CA197289/CA/NCI NIH HHS/United States
UG1 CA239758/CA/NCI NIH HHS/United States